On March 4, 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported a late-breaking poster presentation for its AUTO1 program at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019 to be held March 29 to April 3 in Atlanta, Georgia (Press release, Autolus, MAR 4, 2019, View Source [SID1234550831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation details are as follows. The full text of the abstract will be posted to the AACR (Free AACR Whitepaper) website on March 29.

Abstract Number: CT105
Session Name: PO.CT04 – Phase I-III Trials in Progress: Part 1
TITLE: AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL
Session Date: Monday, April 1, 2019
Session Time: 1:00 PM – 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 17

About AUTO1
AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in safety – while maintaining similar levels of efficacy – compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, AUTO1 may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the T cells’ abilities to engage in serial killing of target cancer cells. In 2018, Autolus signed a license agreement under which Autolus acquired global rights from UCL Business plc (UCLB), the technology-transfer company of UCL, to develop and commercialize AUTO1 for the treatment of B cell malignancies. AUTO1 is currently being evaluated in two Phase 1 studies, one in paediatric ALL and one in adult ALL.
For information about the trials, visit View Source and View Source

On March 4, 2019 Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that Dr. Christian Itin, chairman and chief executive officer, will present at the Cowen and Company 39th Annual Healthcare Conference in Boston, on March 11, at 2:10 pm ET (Press release, Autolus, MAR 4, 2019, https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-present-cowen-and-company-39th-annual [SID1234550822]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the investor relations section of the company’s website: View Source An archived replay will be available on the company’s website for a period of 90 days after the conference.

On March 4, 2019 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 11:20 AM ET in Boston, MA (Press release, Jounce Therapeutics, MAR 4, 2019, https://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-present-cowen-and-company-39th-annual-health [SID1234535388]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting "Events & Presentations" in the Investors and Media section of the company’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation

On March 4, 2019 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, reported that the Company’s fourth quarter 2018 financial results will be released on Thursday, March 7, 2019 (Press release, Calithera Biosciences, MAR 4, 2019, View Source [SID1234535227]). Company management will host a conference call on Thursday, March 7, 2019 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The conference call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and refer to conference ID 9577446. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30 days.

On March 4, 2019 March 04, 2019 Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, reported it will present a poster on the performance of its lead investigational drug, lasofoxifene, at ENDO 2019, the annual meeting of the Endocrine Society (Press release, Sermonix Pharmaceuticals, MAR 4, 2019, View Source [SID1234534381]). The abstract, "Lasofoxifene Achieves Potent Anti-Tumor Activity in Y537S ESR1 Hormone-Resistant Breast Cancer Cells by Saturating ERα," will be presented Sunday, March 24, in a 1-3 p.m. poster session at the Ernest N. Morial Convention Center in New Orleans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sermonix, which is currently enrolling patients in a Phase 2 clinical study of lasofoxifene, collaborated with researchers at the University of Chicago on the poster to be presented at ENDO 2019.

"Our laboratory has been looking for potent, effective inhibitors of tumor progression and metastases, especially in hormone-resistant tumors, so we were excited to observe the significant efficacy of lasofoxifene," said Dr. Geoffrey Greene, Ph.D., chair of the Ben May Department for Cancer Research at the University of Chicago, and the poster’s senior author. "We look forward to detailing our findings at ENDO 2019."

One of the primary goals of collaborating with the University of Chicago was to support Sermonix’s preclinical program – supplementing lasofoxifene’s well-characterized pharmacology – with further study of recently discovered activity in metastatic breast cancers harboring estrogen receptor mutations, according to Barry Komm, Ph.D., Sermonix chief scientific officer.

"This new data collection from Dr. Greene and team is helping us achieve that goal, continuing our momentum toward developing lasofoxifene as a potential novel precision medicine for women diagnosed with treatment-resistant metastatic breast cancer," said Komm.

The U.S. Food and Drug Administration in December accepted Sermonix’s Investigational New Drug application, indicating the company could proceed directly to a Phase 2 clinical study of lasofoxifene. The open-label, randomized, multi-center study will evaluate the activity of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation.